Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

How to apply for vascepa's patient assistance?
Mobic injection patent oehringer ingelheim france?
What is the difference between apixaban and apixaban accord?
Bortezomib market france?
Antiox mebendazole price?

Fda purple book dupilumab biosimilar?

FDA Purple Book and Dupilumab – Current Status

Topic Details
What is the FDA Purple Book? An online database that lists all biologic products (originals & biosimilars) approved by the FDA under the Biologics Price Competition and Innovation Act (BPCIA). It includes product names, manufacturer, approval dates, and whether the product is a “biosimilar” or “interchangeable.”
Dupilumab (brand Dupixent®) A fully human monoclonal antibody used to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. The original product is approved and listed as a “reference biologic” in the Purple Book.
Dupilumab Biosimilars – Are any listed? None are currently approved or listed in the Purple Book as of the latest update (early 2026). Several companies have filed Investigational New Drug (IND) applications or Phase III studies, but no biosimilar has received FDA approval yet.
What’s the next step? Companies that have completed the regulatory pathway (Biologics License Application, BLA) will be added to the Purple Book upon approval. Until that happens, physicians and pharmacists must use the reference product (Dupixent).
Why might a dupilumab biosimilar be delayed? 1. Clinical trial complexity: Dupilumab’s mechanism involves blocking IL‑4 and IL‑13 signaling; demonstrating biosimilarity for immunogenicity and efficacy in multiple indications requires large, well‑controlled trials.
2. Patent & exclusivity: The original product enjoys market exclusivity and patent protection for several years, which can delay biosimilar entry.
3. Manufacturing challenges: Biosimilars must match the reference product’s structural, functional, and safety profile precisely, which is technically demanding.
How to stay updated 1. FDA Purple Book website – check the “Dupilumab” entry or search by manufacturer.
2. FDA’s “Biosimilar and Biosimilar/Interchangeable Approvals” page – lists all newly approved biosimilars.
3. ClinicalTrials.gov – follow ongoing Phase III trials for dupilumab biosimilars.
Implications for clinicians - Current practice: Use Dupixent® or other FDA‑approved biologics.
- Future possibilities: Once a dupilumab biosimilar is approved, formulary decisions and insurance coverage will dictate when it becomes available.
- Cost considerations: Biosimilars typically offer lower cost options, potentially improving access.

Bottom line: As of now, the FDA Purple Book lists only the reference dupilumab product; no dupilumab biosimilar has been approved. Keep an eye on the Purple Book and FDA announcements for any new entries.



Other Questions About Purple :

purple book dupilumab biosimilar Fda purple book humira biosimilar launch 2023 patent settlements? Purple orange book difference? Purple book dupilumab biosimilar official? Purple book? Fda purple book dupilumab biosimilar approved 2025? Is wockhardt purple?